Niagen Bioscience (NAGE) Payables (2011 - 2026)
Niagen Bioscience (NAGE) posted quarterly Payables of $13.3 million for Q1 2026, up 24.88% year-over-year from $10.6 million in Q1 2025, and up 22.98% quarter-over-quarter from $10.8 million in Q4 2025.
Niagen Bioscience (NAGE) Payables (2011 - 2026) Analysis & Trends
Niagen Bioscience (NAGE) has reported Payables for 14 consecutive years, with $13.3 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Payables rose 24.88% year-over-year to $13.3 million; the TTM figure through Mar 2026 stood at $13.3 million (up 24.88% YoY), while the FY2025 annual figure was $10.8 million, up 26.62% from the prior year.
- Payables improved to $13.3 million in Q1 2026 per NAGE's latest filing, from $10.8 million in the prior quarter.
- Across five years, Payables topped out at $13.7 million in Q2 2025 and bottomed at $6.9 million in Q3 2024.
- Historically, Payables has averaged $10.0 million across 5 years, with a median of $9.8 million in 2022.
- Annual changes were most pronounced in 2024 — Payables fell 24.95% — and 2025, when it surged 84.59%.
- Niagen Bioscience's Payables stood at $9.7 million in 2022, then climbed by 5.71% to $10.2 million in 2023, then fell by 16.67% to $8.5 million in 2024, then increased by 26.62% to $10.8 million in 2025, then rose by 22.98% to $13.3 million in 2026.
- Business Quant data shows NAGE's Payables at $13.3 million in Q1 2026, $10.8 million in Q4 2025, and $12.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.52 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 88.42 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 470.30 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.05 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 35.57 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 108.02 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 428.93 Mn |
| 10 | Niagen Bioscience | 238.30 Mn | 171.56 Mn | 19.31 Mn | 9.44 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 9.44 Mn |
| Mar 31, 2026 | 13.28 Mn |
| Dec 31, 2025 | 10.80 Mn |
| Sep 30, 2025 | 12.74 Mn |
| Jun 30, 2025 | 13.68 Mn |
| Mar 31, 2025 | 10.63 Mn |
| Dec 31, 2024 | 8.53 Mn |
| Sep 30, 2024 | 6.90 Mn |
| Jun 30, 2024 | 8.11 Mn |
| Mar 31, 2024 | 7.90 Mn |
| Dec 31, 2023 | 10.23 Mn |
| Sep 30, 2023 | 9.20 Mn |
| Jun 30, 2023 | 10.03 Mn |
| Mar 31, 2023 | 8.95 Mn |
| Dec 31, 2022 | 9.68 Mn |
| Sep 30, 2022 | 9.12 Mn |
| Jun 30, 2022 | 10.20 Mn |
| Mar 31, 2022 | 9.78 Mn |
| Dec 31, 2021 | 10.42 Mn |
| Sep 30, 2021 | 10.80 Mn |